Viridian Therapeutics Highlights Recent Business Progress and Reports Second Quarter 2026 Financial Results
Viridian Therapeutics has transitioned to a commercial-stage company following the FDA approval and immediate U.S. launch of Lumvoa for thyroid eye disease on June 26, 2026. Early launch metrics indicate strong engagement, with the sales team reaching 95% of core prescribers and positive payer adoption efforts underway. For the second quarter of 2026, the company reported total revenue of $284,000 and a net loss of $127.1 million, with R&D expenses decreasing year-over-year to $71.6 million while SG&A increased to $55.0 million to support the commercial rollout.
Key figures
- Revenue
- 284000
- Net loss
- 127100000
- Rd expenses
- 71600000
- Sga expenses
- 55000000
- Cash position
- 981500000
- Financing proceeds
- 394000000
- Shares outstanding
- 125349092
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.